VSTM – verastem, inc. (US:NASDAQ)
Stock Stats
News
11/20
12:04 am
vstm
Low
Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/6
05:06 pm
vstm
Medium
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
11/6
04:05 pm
vstm
Medium
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
11/1
12:18 pm
vstm
Low
Verastem Oncology submits NDA for ovarian cancer treatment [Yahoo! Finance]
10/31
04:01 pm
vstm
Medium
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
8/8/2024
04:05 pm
VSTM
4.9%
BEAT
5/9/2024
04:02 pm
VSTM
-0.6%
BEAT
3/14/2024
04:05 pm
VSTM
4.8%
MISS
10/18
10:35 am
Reiterates
Outperform
Outperform
Royal Bank of Canada
High
13.0%
10/18
10:35 am
Reiterates
Outperform
Outperform
Royal Bank of Canada
High
13.0%
10/18
09:50 am
Reiterates
Outperform
Outperform
RBC Capital
High
10.7%
10/18
09:50 am
Reiterates
Outperform
Outperform
RBC Capital
High
10.7%
10/18
08:33 am
Reiterates
Buy
Buy
HC Wainwright
High
11.7%
11/14
06:26 pm
vstm
Medium
Form SC 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
11/14
04:56 pm
vstm
Medium
Form SCHEDULE 13G Verastem, Inc. Filed by: Nantahala Capital Management, LLC
11/14
04:39 pm
vstm
Medium
Form SC 13G/A Verastem, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
04:36 pm
vstm
Medium
Form SC 13G Verastem, Inc. Filed by: Alyeska Investment Group, L.P.
11/14
04:31 pm
vstm
Medium
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Show more
Top News Gainers
2/28 Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs 59.4%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
Top News Decliners
4/27 Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I -51.4%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3